VP2 Stock Overview
A specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Valeo Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.005 |
| 52 Week High | €0.23 |
| 52 Week Low | €0.0045 |
| Beta | 1.6 |
| 11 Month Change | 0% |
| 3 Month Change | -79.59% |
| 1 Year Change | -95.10% |
| 33 Year Change | -99.01% |
| 5 Year Change | n/a |
| Change since IPO | -99.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| VP2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -7.0% | -0.4% |
| 1Y | -95.1% | -21.6% | 7.1% |
Return vs Industry: VP2 underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: VP2 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| VP2 volatility | |
|---|---|
| VP2 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine VP2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 70 | Al Moghaddam | www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Valeo Pharma Inc. Fundamentals Summary
| VP2 fundamental statistics | |
|---|---|
| Market cap | €493.38k |
| Earnings (TTM) | -€21.80m |
| Revenue (TTM) | €36.22m |
0.0x
P/S Ratio0.0x
P/E RatioIs VP2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VP2 income statement (TTM) | |
|---|---|
| Revenue | CA$53.38m |
| Cost of Revenue | CA$41.36m |
| Gross Profit | CA$12.02m |
| Other Expenses | CA$44.14m |
| Earnings | -CA$32.12m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 22.51% |
| Net Profit Margin | -60.18% |
| Debt/Equity Ratio | -110.1% |
How did VP2 perform over the long term?
See historical performance and comparison